MIGUEL JOSÉ
MARTÍN JIMÉNEZ
Catedrático de universidad
![Foto de MIGUEL JOSÉ](/img/nophoto.png)
![Foto de Hospital Universitario La Fe](/img/noimage_org.png)
Hospital Universitario La Fe
Valencia, EspañaPublications en collaboration avec des chercheurs de Hospital Universitario La Fe (19)
2022
2019
-
Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)
Scientific Reports, Vol. 9, Núm. 1
2018
-
Outcomes of single versus double hormone receptor–positive breast cancer. A GEICAM/9906 sub-study
European Journal of Cancer, Vol. 94, pp. 199-205
2017
-
Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM “El Álamo III” retrospective study
PLoS ONE, Vol. 12, Núm. 10
-
New clinical trials regulation in Spain: analysis of royal decree 1090/2015
Clinical and Translational Oncology, Vol. 19, Núm. 3, pp. 291-300
2016
-
SEOM guidelines 2016: an update
Clinical and Translational Oncology
2015
-
Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: Long-term results of the Spanish GCR-3 phase II randomized trial
Annals of Oncology, Vol. 26, Núm. 8, pp. 1722-1728
-
Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: Results from the GEICAM/2003-10 study
Journal of Clinical Oncology, Vol. 33, Núm. 32, pp. 3788-3795
2014
-
Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: Results from the GEICAM 9906 trial
Breast Cancer Research, Vol. 16, Núm. 2
-
Predicting response and survival in chemotherapy-treated triple-negative breast cancer
British Journal of Cancer, Vol. 111, Núm. 8, pp. 1532-1541
2013
-
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer
Breast Cancer Research and Treatment, Vol. 138, Núm. 2, pp. 457-466
2012
-
PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers
BMC Medical Genomics, Vol. 5
2010
-
Adjuvant docetaxel for high-risk, node-negative breast cancer
New England Journal of Medicine, Vol. 363, Núm. 23, pp. 2200-2210
-
Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer
Breast Cancer Research and Treatment, Vol. 123, Núm. 1, pp. 149-157
2008
-
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer
Journal of the National Cancer Institute, Vol. 100, Núm. 11, pp. 805-814
-
Time-to-progression in breast cancer: A stratification model for clinical trials
Breast, Vol. 17, Núm. 3, pp. 239-244
2007
-
Influence of timing of initiation of adjuvant chemotherapy over survival in breast cancer: A negative outcome study by the Spanish breast cancer research group (GEICAM)
Breast Cancer Research and Treatment, Vol. 101, Núm. 2, pp. 215-223
2006
-
The «El Álamo» project (1990-1997): Two consecutive hospital-based studies of breast cancer outcomes in Spain
Clinical and Translational Oncology, Vol. 8, Núm. 7, pp. 508-518
2005
-
Improvement of breast cancer relapse prediction in high risk intervals using artificial neural networks
Breast Cancer Research and Treatment, Vol. 94, Núm. 3, pp. 265-272